Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Non-Current Liabilities (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $69.8 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 70.48% to $69.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $69.8 million through Dec 2025, up 70.48% year-over-year, with the annual reading at $69.8 million for FY2025, 70.48% up from the prior year.
  • Total Non-Current Liabilities hit $69.8 million in Q4 2025 for Prelude Therapeutics, up from $33.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $69.8 million in Q4 2025 to a low of $33.1 million in Q1 2024.